The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2022 | Latest updates in the management of immune thrombocytopenia
Gillian Lowe MA, MB BChir, MRCP, FRCPath, PhD, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, shares some updates on the management of immune thrombocytopenia (ITP). Dr Lowe first highlights the importance of new Phase II studies in ITP, such as the FLIGHT trial (NCT03156452) and another trial looking at upfront romiplostim alongside dexamethasone for the treatment of ITP patients in the UK. Additionally, Dr Lowe discusses ADA2 deficiency as a potential cause of stroke in young patients and concludes by sharing some insights into the future of ITP, including novel agents and immunosuppressants, and the importance of giving patients a choice when choosing medications. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
Disclosures
Gill Lowe has received honoraria for participating in educational events from Novartis, Leo, Sobi, Alexion, Takeda, NovoNordisk and Sanofi.
